A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This trial will test the hypothesis that CF102 can safely and effectively suppress viral load
in patients with chronic hepatitis C and high circulating levels of virus. The trial will
monitor the safety of twice-daily oral dosing with CF102 over a 16-week period; will measure
changes in viral load during therapy; and will measure blood concentrations of CF102 at
various time points during dosing.